Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psilocybin's effect on human brain synaptic plasticity.

Translational psychiatry·2026
Same authorSame journal

Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

High-Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Longitudinal Decline in Electrochemical Skin Conductance Reflects Disease Progression in Multiple System Atrophy.

European journal of neurology·2026
Same author

Assessment of Dose Proportionality and the Effect of Food on a Once-Daily Extended-Release Tablet Formulation of Deutetrabenazine in Healthy Participants.

Clinical drug investigation·2026
Same author

Clinical and Immunovirological Characteristics Associated with Cardiovascular Dysautonomia in Long COVID.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Jun 5, 2026

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.5K

Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.

Florian Krismer1,2, Patrice Péran3, Vincent Beliveau1,2

  • 1Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Movement Disorders : Official Journal of the Movement Disorder Society
|November 7, 2023
PubMed
Summary

Multiple system atrophy (MSA) patients exhibit significant brain atrophy, particularly in the cerebellum, pons, and putamen, over one year. These findings highlight key areas for monitoring disease progression in MSA.

Keywords:
MRIbrain atrophymultiple system atrophyprogression

More Related Videos

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.2K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 5, 2026

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
09:33

Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases

Published on: July 28, 2013

28.5K
Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
09:06

Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

Published on: June 9, 2018

12.2K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarkers

Background:

  • Biomarkers for disease progression are crucial for multiple system atrophy (MSA) management.
  • Previous magnetic resonance imaging (MRI) studies on MSA brain atrophy yielded inconsistent results.
  • Advanced MRI techniques allow for automated and reliable quantification of brain atrophy.

Purpose of the Study:

  • To quantify in vivo brain atrophy progression rates in patients with multiple system atrophy (MSA).
  • To compare atrophy rates in MSA patients with early-stage Parkinson's disease (PD) and healthy controls (HC).

Main Methods:

  • Serial 3D-T1-weighted MRI scans from 43 MSA patients (baseline and 1-year follow-up) were analyzed.
  • FreeSurfer's longitudinal analysis stream was employed for observer-independent atrophy rate determination.
  • Data were compared against cohorts of early-stage PD patients and healthy controls.

Main Results:

  • Patients with MSA demonstrated significant annual atrophy rates in key brain regions: cerebellar cortex (-4.24%), cerebellar white matter (-8.22%), pons (-4.67%), and putamen (-4.25%).
  • In contrast, Parkinson's disease patients exhibited minimal atrophy rates, comparable to healthy controls.
  • The cerebellum, pons, and putamen showed the most substantial volume loss in MSA patients.

Conclusions:

  • Multiple system atrophy is characterized by significant brain volume loss over a 12-month period.
  • Cerebellar, pontine, and putaminal regions are most sensitive to volumetric changes in mid-stage MSA.
  • These findings establish crucial imaging biomarkers for tracking MSA progression.